LYZL4

Across TCGA pan-cancer cohorts, LYZL4 RNA is linked to patient survival in 15 of 34 cancer types, making it the most broadly survival-associated LYZL4 data layer compared with 3 for mutation status.

The strongest signal is observed in kidney chromophobe (KICH), where higher LYZL4 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated LYZL4 expression acts as an unfavorable survival marker, although some lineages such as READ show a favorable association.

KICH, ACC, and CHOL are the cancer types where LYZL4 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	OS	Tertile	III,IV	0.178	0.847	<.001	78	view →
ACC	DFS	Tertile	III,IV	0.138	0.503	.001	57	view →
CHOL	OS	Tertile	All	0.019	0.800	<.001	54	view →
LIHC	OS	Tertile	III,IV	0.159	0.667	<.001	36	view →
KIRC	DFS	Tertile	IV	0.297	0.519	.023	20	view →
THCA	OS	Tertile	IV	0.579	1.000	<.001	18	view →
COAD	OS	Tertile	II,III,IV	0.476	0.771	.014	15	view →
ESCA	DFS	Median	All	0.307	0.841	.011	14	view →
PCPG	OS	Tertile	All	0.774	0.981	.010	12	view →
BLCA	OS	Tertile	IV	0.207	0.505	.012	9	view →
SCLC	DFS	Tertile	II,III,IV	0.192	0.752	.038	9	view →
UCS	OS	Quartile	II,III,IV	0.195	0.504	.041	8	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 15 lineages.

LYZL4–KICH (OS)

Open the KICH breakdown →